EMERYVILLE and LOS ALTOS, Calif., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, and Genome Compiler Corp., a synthetic biology platform company, today announced the availability of an open testing program for pharma and biotech companies to explore DNA design and construction solutions. The two companies announced a collaboration agreement in March 2015 to integrate Amyris's automated lab services with Genome Compiler's online design tools and e-commerce platform to enable users to design and order DNA or other biological products seamlessly. Today, the companies are extending an open invitation to interested parties to visit Genome Compiler's website page (link here) where they can source helpful information and express their interest in the program.
Researchers Can Achieve More – In Less Time at Lower Cost
Through the integrated platform, researchers can leverage a comprehensive solution from design to delivery that represents a first-of-its-kind integrated DNA design and construction service. The service allows for greater levels of automation, enabling faster progress, and will be less expensive and more sophisticated than other available offerings. Prospective customers will have access to Genome Compiler's advanced software tools, along with Amyris's extensive libraries of verified genetic parts, DNA construction and editing methods, all derived from its expertise in innovative bioscience technology.
"Amyris's leadership role in bioscience technology has enabled us to secure legacy expertise in DNA construction research and automation to speed development and reduce costs," said Joel Cherry, President of Research & Development at Amyris. "Today, we are able to open up key aspects of our DNA design and construction platform services, technical aptitude and knowledge base in synch with Genome Compiler's powerful software tools to provide a fully integrated platform for companies and others seeking to pursue synthetic biology solutions."
"We're pleased to announce the availability of this testing program with Amyris so quickly after announcing our partnership," said Omri Amirav Drory, CEO of Genome Compiler. "We have been working closely with Amyris in recent months and are excited by what we have achieved in creating a truly integrated genomic research platform providing a unique outsourced solution for any organization's synthetic biology development needs along with the ability to achieve significant time and cost savings."
This joint project between Amyris and Genome Compiler has been funded in part by a grant from the Binational Industrial Research and Development Foundation (BIRD Foundation), a U.S.-Israeli partnership between private sectors to expand private high-tech industries.
Amyris is the integrated renewable products company that is enabling the world's leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. The company is delivering its No Compromise® products in focused markets, including specialty and performance chemicals, fragrance ingredients, and cosmetic emollients. More information about the company is available at www.amyris.com.
About Genome Compiler
Genome Compiler is a leader in computer aided design and collaboration platforms for the synthetic biology industry. Based in Los Altos, CA and Tel-Aviv, Israel, Genome Compiler's CAD tool and marketplace platform allows scientists in the biotechnology, agriculture and pharmaceutical industries to design, debug and compile biological code, to develop better bio-based products faster. More information about Genome Compiler is available at www.genomecompiler.com.
This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as the anticipated launch of an integrated DNA design and construction service platform and expected cost savings and other benefits provided by the platform over existing offerings), that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including those associated with any delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris's reliance on third parties to achieve its goals, and other risks detailed in the "Risk Factors" section of Amyris's quarterly report on Form 10-Q filed on May 7, 2015. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.
Amyris and the Amyris logo are registered trademarks of Amyris, Inc. All other trademarks are the property of their respective owners.
CONTACT: Peter DeNardo Director, Investor Relations and Corporate Communications Amyris, Inc. +1 (510) 740-7481 email@example.com firstname.lastname@example.org Omri Amirav-Drory CEO Genome Compiler Corp. +1 (510) 316-6584 email@example.com
Source:Amyris, Inc.;Genome Compiler Corp.